ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > PD-L1

PD-L1

概要

Name:Programmed death-ligand 1
Target Synonym:HPD-L1,Programmed Cell Death 1 Ligand 1,PDCD1L1,B7H1,PDL1,Programmed Death Ligand 1,B7-H1,B7-H,B7-H1 Antigen,CD274,B7 homolog 1,PDCD1 ligand 1,PD-L1,PDCD1LG1,CD274 Molecule,CD274 Antigen
Number of Launched Drugs:7
Number of Drugs in Clinical Trials:156
Lastest Research Phase:Phase 2 Clinical

製品リスト製品比較と製品注文

製造番号 種類 製品説明 構造 純度 特徴
PD1-HP2H3 Human PE-Labeled Human PD-L1 / B7-H1 (19-238) Protein, His TagStar Staining
PD1-H5213 Human Human PD-L1 / B7-H1 Protein, Tag Free (MALS verified)
PD1-H5213-structure
PD1-H5213-sds
PD1-C82F3 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)
PD1-C82F3-structure
PD1-C82F3-sds
PDL-M82E7 Mouse Biotinylated Mouse PD-L1 / B7-H1 Protein, His,Avitag™ (MALS verified)
PDL-M82E7-structure
PDL-M82E7-sds
HCS-S240 Rabbit Recombinant Monoclonal Anti-PD-L1 Antibody, Rabbit (5D3)
EP-157 Mouse Mouse PD-L1 : Mouse PD-1 [Biotinylated] Inhibitor Screening ELISA Kit
SCCHO-ATP077M Human CHO/Human PD-L1 Stable Cell Line (Medium Expression) Development Service
SCCHO-ATP077H Human CHO/Human PD-L1 Stable Cell Line (High Expression) Development Service
SCCHO-ATP077L Human CHO/Human PD-L1 Stable Cell Line (Low Expression) Development Service
SCRAJ-STT075 Human Raji/Human PD-L1 Stable Cell Line Development Service
EP-133 Human PD-L1 : PD-1 [Biotinylated] Inhibitor Screening ELISA Kit
PDL-C82E8 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His,Avitag™ (MALS verified)
PDL-C82E8-structure
PDL-C82E8-sds
PDL-C52H4 Canine Canine PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PDL-C52H4-structure
PDL-C52H4-sds
PD1-H82A3 Human Biotinylated Human PD-L1 / B7-H1 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
PD1-H82A3-structure
PD1-H82A3-sds
PD1-H52H3 Human Human PD-L1 / B7-H1 (19-134) Protein, His Tag (MALS verified)
PD1-H52H3-structure
PD1-H52H3-sds
PD1-C52H3 Canine Canine PD-L1 / B7-H1 Protein, Fc Tag
PD1-C52H3-structure
PD1-C52H3-sds
PDL-H82E4 Human Biotinylated Human PD-L1 / B7-H1 (19-134) Protein, His,Avitag™ (recommended for biopanning) (MALS verified)
PDL-H82E4-structure
PDL-H82E4-sds
PDL-R52H6 Rabbit Rabbit PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PDL-R52H6-structure
PDL-R52H6-sds
PDL-H5250 Human Human PD-L1 / B7-H1 Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified)
PDL-H5250-structure
PDL-H5250-sds
PDL-H82F2 Human Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)
PDL-H82F2-structure
PDL-H82F2-sds
PD1-M52A2 Mouse Mouse PD-L1 / B7-H1 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
PD1-M52A2-structure
PD1-M52A2-sds
PD1-H82E5 Human Biotinylated Human PD-L1 / B7-H1 Protein, Avitag™,His Tag (MALS verified)
PD1-H82E5-structure
PD1-H82E5-sds
PD1-M82F5 Mouse Biotinylated Mouse PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)
PD1-M82F5-structure
PD1-M82F5-sds
PD1-M5220 Mouse Mouse PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PD1-M5220-structure
PD1-M5220-sds
PD1-M5251 Mouse Mouse PD-L1 / B7-H1 Protein, Fc Tag (MALS verified)
PD1-M5251-structure
PD1-M5251-sds
PD1-H52A3 Human Human PD-L1 / B7-H1 Protein, Mouse IgG1 Fc Tag, low endotoxin (MALS verified)
PD1-H52A3-structure
PD1-H52A3-sds
PD1-C52H4 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PD1-C52H4-structure
PD1-C52H4-sds
PD1-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, Fc Tag (MALS verified)
PD1-C5253-structure
PD1-C5253-sds
PD1-H82F3 Human Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™,His Tag (MALS verified)
PD1-H82F3-structure
PD1-H82F3-sds
PD1-H5282 Human Human PD-L1 / B7-H1 Protein, Twin-Strep Tag (HPLC verified)
PD1-H5282-structure
PD1-H5282-sds
PD1-H5282-hplc
PD1-H5258 Human Human PD-L1 / B7-H1 Protein, Fc Tag (MALS verified)
PD1-H5258-structure
PD1-H5258-sds
PD1-H5229 Human Human PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PD1-H5229-structure
PD1-H5229-sds
ACRO Quality

生物活性データの一部

SCCHO-ATP077M-Cell-based assay
 PD-L1 FACS

Expression analysis of human PD-L1 on CHO/ Human PD-L1 Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human PD-L1 antibody was performed on CHO/Human PD-L1 Stable Cell Line with different expression levels: CHO/Human PD-L1 Stable Cell Line (Low Expression); CHO/Human PD-L1 Stable Cell Line (Medium Expression); CHO/Human PD-L1 Stable Cell Line (High Expression).

SCCHO-ATP077H-Cell-based assay
 PD-L1 FACS

Expression analysis of human PD-L1 on CHO/ Human PD-L1 Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human PD-L1 antibody was performed on CHO/Human PD-L1 Stable Cell Line with different expression levels: CHO/Human PD-L1 Stable Cell Line (Low Expression); CHO/Human PD-L1 Stable Cell Line (Medium Expression); CHO/Human PD-L1 Stable Cell Line (High Expression).

PD1-C82F3-SPR
 PD-L1 SPR

Biotinylated Cynomolgus / Rhesus macaque PD-L1 Protein, Fc,Avitag (Cat. No. PD1-C82F3) captured on Protein A Chip can bind Cynomolgus PD-1 Protein, His Tag (Cat. No. PD1-C52H5) with an affinity constant of 3.09 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

PDL-C82E8-SPR
 PD-L1 SPR

Cynomolgus PD-1, Fc Tag (Cat. No. PD1-C5254) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Biotinylated Cynomolgus / Rhesus macaque PD-L1, His,Avitag (Cat. No. PDL-C82E8) with an affinity constant of 6.59 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

カスタマーレビュー

Synonym Name

PD-L1,CD274,B7-H1,PDCD1L1,PDCD1LG1

Background

Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Avelumab PF-06834635; MSB-0010718C Approved Merck Serono Bavencio EU Carcinoma, Transitional Cell Merck Europe Bv 2017-03-23 Lymphoma, Large-Cell, Anaplastic; Microsatellite Instability; Lymphoma, Extranodal NK-T-Cell; Peritoneal Neoplasms; Sezary Syndrome; Meningeal Neoplasms; Testicular Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Acute; Lymphoma; Thymoma; Fallopian Tube Neoplasms; Lymphoma, T-Cell; Neuroendocrine Tumors; Testicular Diseases; Penile Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Mycosis Fungoides; Neoplasm Metastasis; Meningioma; Neoplasms, Germ Cell and Embryonal; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Hepatocellular; Hodgkin Disease; Ovarian Neoplasms; Lymphoma, T-Cell, Peripheral; Kidney Neoplasms; Lymphoma, B-Cell; Stomach Neoplasms; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Solid tumours; Lymphoma, Large B-Cell, Diffuse; Gonadal Disorders; Carcinoma, Transitional Cell; Details
Durvalumab 28X28X9-OKV (UNII code); MEDI-4736 Approved Medimmune Llc 英飞凡, Imfinzi United States Biliary Tract Neoplasms Astrazeneca Uk Ltd 2018-02-16 Urologic Neoplasms; Laryngeal Neoplasms; Lip Neoplasms; Mouth Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Carcinoma, Small Cell; Lymphoma; Leukemia, Myeloid, Acute; Lung Neoplasms; Ureteral Neoplasms; Fallopian Tube Neoplasms; Sezary Syndrome; Pinealoma; Testicular Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Primary Myelofibrosis; Oropharyngeal Neoplasms; Colorectal Neoplasms; Microsatellite Instability; Urethral Neoplasms; Carcinoma, Hepatocellular; Dysgerminoma; Mycosis Fungoides; Neoplasms, Germ Cell and Embryonal; Laryngeal Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Endometrioid; Melanoma; Adenocarcinoma; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Neoplasms; Esophageal adenocarcinoma; Gallbladder Neoplasms; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Appendiceal Neoplasms; Thyroid Neoplasms; Lymphoma, T-Cell, Cutaneous; Stomach Neopla Details
Atezolizumab RO-5541267; 52CMI0WC3Y (UNII code); RG-7446; MPDL-3280A Approved Genentech Inc 泰圣奇, Tecentriq Mainland China Carcinoma, Non-Small-Cell Lung Roche (China) Holding Ltd 2016-05-18 Genital Neoplasms, Female; Lymphoma, T-Cell, Cutaneous; Penile Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Oropharyngeal Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Lymphoma; Sezary Syndrome; Peritoneal Neoplasms; Prostatic Neoplasms; Sarcoma, Clear Cell; Lymphoma, Follicular; Sarcoma; Breast Neoplasms; Urethral Neoplasms; Glioma; Liposarcoma, Myxoid; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Uterine Cervical Neoplasms; Gastrointestinal Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Multiple Myeloma; Laryngeal Neoplasms; Sarcoma, Alveolar Soft Part; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Thymoma; Urogenital Neoplasms; Neoplasms, Unknown Primary; Carcinoma; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Anus Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Neoplasms; Kidney Neo Details
Sugemalimab WBP-3155; CS-1001 Approved Cstone Pharmaceuticals (Suzhou) Co Ltd 择捷美 Mainland China Carcinoma, Non-Small-Cell Lung Cstone Pharmaceuticals (Suzhou) Co Ltd 2021-12-20 Urinary Bladder Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Lymphoma; Lymphoma, T-Cell; Colorectal Neoplasms; Prostatic Neoplasms; Lymphoma, Extranodal NK-T-Cell; Solid tumours; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Hodgkin Disease; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms Details
Envafolimab KN-035; ASC-22 Approved 3d Medicines (Sichuan) Co Ltd, Suzhou Alphamab Co Ltd ENWEIDA, 恩维达 Mainland China Mismatch Repair Deficient Cancer; Microsatellite instability-high cancer 3d Medicines (Sichuan) Co Ltd 2021-11-25 Dermatofibrosarcoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Sarcoma; Microsatellite instability-high cancer; Sepsis; Neoplasms; Solid tumours; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Hepatitis B, Chronic; Liver Neoplasms; Shock, Septic; HIV Infections Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) Phase 1 Clinical Jiangsu Huaiyu Pharmaceutical Co Ltd Solid tumours Details
IMM2505 IMM2505 Phase 1 Clinical Shenghe (China) Biopharmaceutical Co Ltd Solid tumours Details
89Zr-KN035(Wuxi No. 4 People's Hospital) Clinical Wuxi No. 4 People Solid tumours Details
Carrizumab Phase 2 Clinical Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma Details
PM-1003 PM1003 Phase 2 Clinical Biotheus Inc Solid tumours Details
18F-BMS-986192 BMS-986192-[18F] Clinical Neoplasms Details
ADG-104 ADG-104; ADG104 Phase 2 Clinical Guilin Sanjin Pharmaceutical Co Ltd, Adagene Inc Neoplasms Details
JS-003 JS-003 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours Details
RG-6084 RG-6084; RO-7191863 Phase 1 Clinical F. Hoffmann-La Roche Ltd Hepatitis B Details
QL-415 QL-415 Phase 1 Clinical Neoplasms Details
QL-301 QL-301 Phase 1 Clinical Neoplasms Details
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) Phase 2 Clinical Changhai Hospital Of Shanghai Pancreatic Neoplasms Details
SG12473 SG12473; SG-12473 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Hematologic Neoplasms; Solid tumours; Neoplasms Details
LP-008 LP-008 Phase 1 Clinical Lepu Biotech Co Ltd Solid tumours Details
Durvalumab/Selumetinib sulfate Phase 1 Clinical Astrazeneca Plc Neoplasms Details
TT-00420/Atezolizumab Phase 1 Clinical Gastrointestinal Neoplasms Details
Durvalumab/Gefitinib Phase 2 Clinical Medimmune Carcinoma, Non-Small-Cell Lung Details
SKB-337 SKB337; A-337; SKB-337 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Solid tumours Details
PM-1022 PM-1022 Phase 1 Clinical Biotheus Inc Neoplasms Details
IMM-2510 IMM-2510 Phase 1 Clinical Solid tumours Details
FH-2001 FH-2001 Phase 1 Clinical Shanghai Fosun Pharmaceutical Development Ltd Solid tumours Details
CCX-559 CCX-559 Phase 1 Clinical Chemocentryx Inc Solid tumours; Neoplasms Details
KN-052 KN-052 Phase 1 Clinical Solid tumours Details
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) Sichuan University Details
QLS31901 QLS-31901; QLS31901 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Neoplasms Details
TJ-L14B ABL-503; TJ-L14B/ABL503; ABL503 I-Mab Biopharma Co Ltd Details
QLF31907 QLF31907; QLF-31907 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Neoplasms Details
CA-170 CA-170; AUPM-170 Aurigene Details
TQB-2868 TQB-2868 Phase 1 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Neoplasms Details
99mTc-NM-01 99mTc-NM-01 Phase 2 Clinical Nanomab Technology Ltd Carcinoma, Non-Small-Cell Lung Details
BMS-986189 BMS-189; BMS-986189; PD-L1-Milla; BMS-986189-07 Bristol-Myers Squibb Company Details
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) The Second Hospital Of Nanjing Medical University Details
Emdifen Phase 1 Clinical Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences Solid tumours Details
Cosibelimab CK-301; TG-1501 Phase 3 Clinical Dana-Farber Cancer Institute Lymphoma; Carcinoma, Non-Small-Cell Lung Details
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) Phase 1 Clinical Tianjin Mycure Medical Technology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
SHS-006(Nanjing Sanhome Pharmaceutical) SHS-006; SH-006; SH006 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Solid tumours Details
Ori-Bs-001 Ori-Bs-001 Phase 1 Clinical Solid tumours Details
BAT-7104 BAT-7104 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours; Neoplasms Details
GNC-039 GNC-039 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis Details
HB-0028 HB-0028 Phase 2 Clinical Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd Solid tumours Details
Betifisolimab MSB-2311 Phase 1 Clinical Mabspace Biomedicine (Suzhou) Co Ltd Solid tumours Details
ABL-501 ABL-501 Phase 1 Clinical Abl Bio Inc Solid tumours Details
SL-279252 TAK-252; SL-279252 Phase 1 Clinical Takeda Pharmaceutical Co Ltd, Shattuck Labs Inc Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma Details
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase 1 Clinical Hunan Zhaotai Yongren Biotech Co Ltd Carcinoma, Non-Small-Cell Lung Details
Davoceticept ALPN-202 Phase 1 Clinical Alpine Immune Sciences Inc Solid tumours; Lymphoma Details
MT-6402 MT-6402; MT-64-6402 Phase 1 Clinical Molecular Templates Inc Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung Details
Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) LP-002 Phase 2 Clinical Taizhou Houde Aoke Technology Co Ltd Lymphoma, B-Cell; Solid tumours; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma Details
BMS-936559 MDX-1105; BMS-936559 Phase 2 Clinical Bristol-Myers Squibb Company Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Shock, Septic; HIV Infections; Sepsis; Hodgkin Disease; Neoplasms; Small Cell Lung Carcinoma; Multiple Myeloma; Lymphoma, Non-Hodgkin; Melanoma Details
PRS-344 PRS-344/ONC0055; PRS-344; PRS-344/S095012; PRS-344S095012; S-095012 Phase 2 Clinical Pieris Pharmaceuticals Inc, Laboratoires Servier Solid tumours Details
Pd-1-pik Pd-1-pik Phase 1 Clinical Huashan Hospital Affiliated To Fudan University Glioblastoma Details
89Zr-durvalumab Phase 2 Clinical Radboud University Nijmegen Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung Details
CHECKvacc CF33-hNIS-antiPDL1 Phase 1 Clinical Imugene Ltd, City Of Hope National Medical Center Triple Negative Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer Details
TS-1905 TS-1905; LY-01019; BA-1201 Phase 1 Clinical Shandong Boan Biotechnology Co Ltd Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Papillomavirus Infections; Carcinoma, Non-Small-Cell Lung Details
HB-0036 HB-0036 Phase 2 Clinical Huabo Biopharm Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details
PF-07257876 Phase 1 Clinical Pfizer Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung Details
CYTO-102 CYTO-NK-102; CYTO-102; COH06 Phase 1 Clinical CytoImmune Therapeutics Inc Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
SHS-009 SHS-009; SH009; SH-009 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Neoplasms Details
BC008-1A BC008-1A Phase 1 Clinical Sichuan Luzhou Buchang Biopharmaceutical Co Ltd Solid tumours Details
Q-1802 Q-1802 Phase 1 Clinical Qiyu Biotechnology (Shanghai) Co Ltd Solid tumours; Gastrointestinal Neoplasms Details
Garivulimab BGB-A333 Phase 1 Clinical Beigene Ltd Solid tumours; Neoplasms Details
FPT-155 CD80-Fc; FPT-155 Phase 1 Clinical Five Prime Therapeutics Inc Solid tumours; Neoplasms Details
Lesabelimab BC-003 Phase 2 Clinical Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Penile Neoplasms Details
IBI-323(Innovent Biologics) IBI-323 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
ABSK-043 ABSK043 Phase 1 Clinical ABbisko Therapeutics Co Ltd Solid tumours; Neoplasms Details
HLX-301 HLX-301 Phase 2 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
BR-102 BR102 Phase 1 Clinical BioRay Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
AN-4005 AN-4005 Phase 1 Clinical Hangzhou Adlai Nortye Biomedical Technology Co Ltd Solid tumours; Neoplasms; Lymphoma Details
LBL-024 LBL024; LBL-024 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Solid tumours; Neoplasms Details
FS-222 FS-222 Phase 1 Clinical F-star Beta Ltd Neoplasms; Neoplasm Metastasis Details
Sudubrilimab HS-636 Phase 2 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Triple Negative Breast Neoplasms; Neoplasms; Primary mediastinal B cell lymphoma Details
FS 118 FS-118 Phase 2 Clinical Merck Serono, F-Star Squamous Cell Carcinoma of Head and Neck; Neoplasms; Neoplasm Metastasis Details
INBRX-105 ES101; INBRX-105 Phase 1 Clinical Inhibrx Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Esophageal adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Simridarlimab IBI-322; IBI322 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Bone Marrow Neoplasms; Hematologic Neoplasms; Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Lymphoma Details
INCB-099318 INCB-099318; INCB-99318 Phase 1 Clinical Incyte Corp Neoplasms; Uterine Cervical Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Microsatellite instability-high cancer; Mesothelioma; Ovarian Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Anus Neoplasms; Solid tumours Details
Opucolimab HLX-20 Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Solid tumours; Neoplasms Details
MCLA-145 MCLA-145 Phase 1 Clinical Incyte Corp, Merus Nv Solid tumours; Neoplasms Details
INCB-086550 INCB-086550; INCB-86550 Phase 2 Clinical Incyte Corp Solid tumours; Carcinoma, Renal Cell; Carcinoma; Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular Details
LOR-S03 CDX-527 Phase 1 Clinical Celldex Therapeutics Solid tumours; Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Lodapolimab LY-3300054 Phase 1 Clinical Eli Lilly And Company Skin Melanoma; Solid tumours; Carcinoma, Renal Cell; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
FAZ-053 FAZ-053; LAE-005; LAE005 Phase 2 Clinical Novartis Pharma Ag Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Chordoma; Sarcoma, Alveolar Soft Part Details
IBC-Ab002 IBC-Ab002 Phase 1 Clinical ImmunoBrain Checkpoint Inc Alzheimer Disease Details
6MW-3511 6MW-3511 Phase 2 Clinical Mabwell (Shanghai) Bioscience Co Ltd Solid tumours; Neoplasms Details
RAD-203 RAD-203 Phase 1 Clinical Radiopharm Theranostics Ltd Carcinoma, Non-Small-Cell Lung Details
EMB-09 EMB-09 Phase 1 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours Details
6MW-3211 6MW3211; 6MW-3211 Phase 2 Clinical Mabwell (Shanghai) Bioscience Co Ltd Carcinoma, Renal Cell; Neoplasms; Myelodysplastic Syndromes; Lung Neoplasms; Lymphoma; Leukemia, Myeloid, Acute Details
GNC-035 quadr-specific antibody(baili) GNC-035 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer Details
BPI-371153 BPI-371153 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Liver Neoplasms; Solid tumours; Lymphoma; Carcinoma, Non-Small-Cell Lung Details
KD-033 KD-033 Phase 1 Clinical Takeda Pharma Solid tumours Details
Gallium [68Ga] Natan recombinant PD-L1 single domain antibody SNA-002 Phase 1 Clinical Smartnuclide Biopharma Solid tumours; Neoplasms; Contrast agents Details
SIM-0237 SIM-0237 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours Details
Dual-targeting VEGFR1 and PD-L1 CAR-T cells Therapy (Sichuan University) Phase 1 Clinical Sichuan University Serositis; Ascites Details
RC-98 RC-98; RC98 Phase 2 Clinical RemeGen Co Ltd Solid tumours; Stomach Neoplasms Details
CN-202 CN-202 Phase 2 Clinical Tongrun Biomedicine (Shanghai) Co Ltd Solid tumours; Hematologic Neoplasms; Neoplasm Metastasis Details
Erfonrilimab KN-046; KN046 Phase 3 Clinical Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Breast Neoplasms; Thymus Neoplasms; Thymoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Pancreatic Ductal; Lymphoma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular Details
IMM-2520 IMM-2520 Phase 1 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Solid tumours Details
Acasunlimab PD-L1x4-1BB; DuoBody-PD-L1x4-1BB; GEN1046; BNT-311 Phase 2 Clinical Genmab A/S, Biontech Se Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
MAX-10181 MAX-10181; MAX-1 Phase 1 Clinical Guangzhou Maxinovel Pharmaceiticals Co Ltd Solid tumours; Neoplasms Details
HK-010 HK010; HK-010 Phase 1 Clinical Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd Neoplasms Details
BJ-005 BJ-005 Phase 1 Clinical Boji Biomedical Technology (Hangzhou) Co Ltd Solid tumours; Lymphoma Details
TQB-2858 TQB-2858 Phase 2 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Pancreatic Neoplasms; Neoplasms; Nasopharyngeal Neoplasms; Sarcoma; Endometrial Neoplasms; Uterine Cervical Neoplasms Details
SG-1408 SG-1408; SG1408 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Solid tumours Details
TQB-2450 APL-502; CBT-502; TQ-B2450 Phase 3 Clinical Cbt Carcinoma, Squamous Cell; Cholangiocarcinoma; Primary mediastinal B cell lymphoma; Nasopharyngeal Carcinoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Lymphoma; Stroke; Esophageal Squamous Cell Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular; Esophageal Diseases; Melanoma; Gastrointestinal Neoplasms; Esophageal Neoplasms; Solid tumours; Biliary Tract Neoplasms; Lymphoma, B-Cell; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Gastrointestinal Diseases; Digestive System Diseases; Hepatitis B, Chronic; Liver Neoplasms; Genital Diseases, Female; Triple Negative Breast Neoplasms; Hodgkin Disease; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Neoplasms; Neoplasms, Squamous Cell; Digestive System Neoplasms Details
HL-301 HL-301 Phase 2 Clinical Hanlim Pharm Co Ltd Radiation Pneumonitis; Lung Neoplasms Details
INCB-099280 INCB-099280; INCB-99280 Phase 1 Clinical Incyte Corp Ltd Solid tumours; Carcinoma, Merkel Cell; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Mesothelioma; Microsatellite instability-high cancer; Nasopharyngeal Carcinoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular Details
Dimethylaminomicheliolide Fumarate ACT-001 Phase 2 Clinical Accendatech Co Ltd Ganglioglioma; Glioblastoma; Optic Neuritis; Central Nervous System Neoplasms; Neuromyelitis Optica; Breast Neoplasms; Glioma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
ASC-61 ASC-61 Phase 1 Clinical Ascletis Pharma Inc Solid tumours; Neoplasms Details
SGN-PDL1V SGN-PDL1V Phase 1 Clinical Seagen Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
HB-0025 HB0025 Phase 2 Clinical Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd Solid tumours; Carcinoma, Renal Cell Details
ATG-101 ATG-101 Phase 1 Clinical Antengene Corporation Co Ltd Solid tumours; Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma, Non-Hodgkin; Neoplasm Metastasis Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Gallbladder Neoplasms; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Sarcoma; Prostatic Neoplasms; Microsatellite Instability; Breast Neoplasms; Vulvar Neoplasms; Thymus Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms; Thymoma; Lung Neoplasms; Penile Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasm Metastasis; Sarcoma, Kaposi; Stomach Neoplasms; Biliary Tract Neoplasms; Intestinal Neoplasms; Head and Neck Neoplasms; Esthesioneuroblastoma, Olfactory; Carcinoma; Carcinoma, Renal Cell; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Vaginal Neoplasms; Anus Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Ganglioglioma; Nose Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Carcinoma, Transitional Cell; Respiratory papillomatosis; Adenomyoepithelioma Details
PD-L1 t-haNK cell therapy/Inbakicept/Aldoxorubicin Hydrochloride(Immunitybio) Phase 2 Clinical Immunitybio Inc Pancreatic Neoplasms Details
PD-L1 t-haNK cell therapy Phase 2 Clinical Nantkwest Inc Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Neoplasm Metastasis Details
18F-BMS-986229 18F-BMS-986229; [18F]BMS-986229 Phase 2 Clinical Bristol-Myers Squibb International Corp Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details
TST-005 TST-005; TST005 Phase 1 Clinical Mabspace Biomedicine (Suzhou) Co Ltd Solid tumours; Neoplasms; Papillomavirus Infections Details
BS-006 BS-006 Phase 1 Clinical Wuhan Binhui Biotechnology Co Ltd Solid tumours; Melanoma; Uterine Cervical Neoplasms Details
Pacmilimab CX-072 Phase 2 Clinical Cytomx Therapeutics Inc Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Lymphoma; Melanoma Details
Emfizatamab GNC-038 Phase 2 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell Details
sirpiglenastat DRP-104 Phase 2 Clinical Dracen Pharmaceuticals Inc Solid tumours; Carcinoma, Non-Small-Cell Lung Details
PM-8002 PM8002; PM-8002 Phase 2 Clinical Biotheus Inc Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Mesothelioma; Neuroendocrine Tumors; Carcinoma, Hepatocellular Details
GT-90008 GS-19-PLB-1C; GT-90008; GS-19 Phase 1 Clinical Suzhou Kintor Pharmaceuticals Inc Solid tumours Details
ND-021 ND-021; NM21-1480; CS-2006; CS2006 Phase 2 Clinical Numab Therapeutics Ag, Cstone Pharmaceuticals Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Reozalimab IBI-318; LY-3434172; LY3434172 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
MVR-C5252 C-5252; MVR-C5252 Phase 1 Clinical Immvira Co Ltd Solid tumours; Glioblastoma; Ganglioglioma; Brain Neoplasms Details
IMC-001 IMC-001; STI-3031; STI-A1015 Phase 2 Clinical Sorrento Therapeutics Inc Solid tumours; Biliary Tract Neoplasms; Lymphoma, T-Cell, Peripheral; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Neoplasm Metastasis; Melanoma Details
PM-8001 6MW3111; PM-8001 Phase 2 Clinical Biotheus Inc Solid tumours; Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Retlirafusp alfa SHR-1701 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Prostatic Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Recombinant anti-PD-L1/TGF-β bispecific antibody Y101D; Y-101D Phase 1 Clinical Wuhan Yzy Biopharma Co Ltd Solid tumours; Pancreatic Neoplasms Details

This web search service is supported by Google Inc.

totopphone